Stockreport

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Pliant Therapeutics, Inc.  (PLRX) 
PDF PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with [Read more]